About REGN Dividend Returns
Regeneron Pharmaceuticals, Inc. (REGN) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.
How We Calculate Total Return
Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.
Frequently Asked Questions
Q1What is the total return of REGN over the past year?
Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of 19.47% over the past year when dividends are reinvested. The price-only return was 18.76%, meaning dividends contributed an additional 0.71 percentage points to total returns.
Q2How much would $10,000 invested in REGN be worth today?
A $10,000 investment in Regeneron Pharmaceuticals, Inc. one year ago would be worth $11,947 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $11,876. Dividend reinvestment added $71 to the portfolio value.
Q3Does REGN pay dividends?
Yes, Regeneron Pharmaceuticals, Inc. (REGN) pays dividends. In the last year, REGN paid approximately $3.41 per share in dividends (0.56% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.
Q4Did REGN beat the S&P 500?
No, Regeneron Pharmaceuticals, Inc. (REGN) underperformed the S&P 500 by 5.52 percentage points over the past year. REGN delivered a total return of 19.47%, compared to the S&P 500's 24.99%. This means a passive S&P 500 index fund outperformed REGN by 5.52pp during this period.
Q5What is REGN's worst drawdown?
Regeneron Pharmaceuticals, Inc. (REGN) experienced a maximum drawdown of -26.05% over the past year, declining from its peak on 2026-01-07 to its trough on 2026-06-01. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.
Q6What is REGN's long-term total return over 10, 20, or 30 years?
Here are Regeneron Pharmaceuticals, Inc. (REGN)'s long-term returns with dividends reinvested. Over 10 years, the total return is 74.5% (5.7% CAGR) — $10,000 would have grown to $17,449. Over 20 years: 4882.5% total return (21.6% CAGR) — $10,000 → $498,251. Over 30 years: 3656.6% total return (12.8% CAGR) — $10,000 → $375,663. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.
Q7What was REGN's best and worst year?
Regeneron Pharmaceuticals, Inc.'s best calendar year was 2012 with a total return of 203.2%. Its worst year was 1997 with a total return of -50.0%. This range shows the volatility investors should expect — the difference between the best and worst year is 253.2 percentage points.
Find the Best Total Return Stocks
Screen for dividend stocks with the strongest long-term returns, including DRIP compounding.
How much would $100/month in REGN be worth today?
Dollar cost averaging calculator · DCA vs lump sum · see how regular investing compounds
BIIB
VRTX
INCY
BMRN
ABBV
LLY
AMGN
GILD
MRK
PFE